Protagonist Therapeutics (PTGX) News Today $40.69 -0.77 (-1.86%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period State Street Corp Has $143.26 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)State Street Corp grew its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 52.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,183,542 shares of the company's stock after purchasingDecember 14, 2024 | marketbeat.com14,801 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Purchased by XTX Topco LtdXTX Topco Ltd acquired a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 14,801 shares of the company's stock, valued at approximately $666,000. A number of otherDecember 13, 2024 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by BNP Paribas Financial MarketsBNP Paribas Financial Markets boosted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 448.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,294 shares of the company's stock after puDecember 12, 2024 | marketbeat.comPromising Prospects for Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Efficacy and Competitive EdgeDecember 11, 2024 | markets.businessinsider.comOptimistic Buy Rating for Protagonist Therapeutics Driven by Promising Rusfertide Data and Strategic Takeda PartnershipDecember 11, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX)December 11, 2024 | americanbankingnews.comProtagonist Therapeutics' (PTGX) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $50.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday.December 10, 2024 | marketbeat.comFmr LLC Purchases 19,737 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Fmr LLC grew its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 4.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 454,196 shares of the company's stock after acquiring an additional 19,737 shares during theDecember 10, 2024 | marketbeat.comProtagonist Therapeutics announces data from REVIVE study at ASHDecember 10, 2024 | markets.businessinsider.comWeiss Asset Management LP Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Weiss Asset Management LP acquired a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 62,463 shares of the company's stock, valued at aDecember 8, 2024 | marketbeat.comPoint72 Asset Management L.P. Cuts Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Point72 Asset Management L.P. decreased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 76.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 214,872 shares of the company'sDecember 8, 2024 | marketbeat.comBMO Capital Markets Initiates Coverage on Protagonist Therapeutics (NASDAQ:PTGX)December 8, 2024 | americanbankingnews.comBMO Capital Initiates Coverage of Protagonist Therapeutics (PTGX) with Outperform RecommendationDecember 6, 2024 | msn.comHold Rating Maintained for Protagonist Therapeutics Amid Promising Phase 3 Assets and Limited Financial Upside Due to Licensing AgreementsDecember 6, 2024 | markets.businessinsider.comProtagonist Therapeutics price target raised to $58 from $43 at JMP SecuritiesDecember 6, 2024 | finance.yahoo.comBuy Rating Affirmed for Protagonist Therapeutics: Innovative Peptide Platform and Promising Pipeline Drive Growth ProspectsDecember 6, 2024 | markets.businessinsider.comProtagonist Therapeutics (NASDAQ:PTGX) Now Covered by The Goldman Sachs GroupThe Goldman Sachs Group initiated coverage on shares of Protagonist Therapeutics in a research report on Friday. They issued a "neutral" rating and a $47.00 target price for the company.December 6, 2024 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Now Covered by Analysts at BMO Capital MarketsBMO Capital Markets assumed coverage on Protagonist Therapeutics in a report on Friday. They set an "outperform" rating and a $62.00 target price for the company.December 6, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Boosts Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Charles Schwab Investment Management Inc. raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 7.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 565,503 shares ofDecember 6, 2024 | marketbeat.comRTW Investments LP Acquires 139,708 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)RTW Investments LP raised its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 2.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,426,112 shares of the company's stock after purchasing an additional 139,December 5, 2024 | marketbeat.comHighVista Strategies LLC Boosts Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)HighVista Strategies LLC boosted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 321.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 89,508 shares of the company's stockDecember 3, 2024 | marketbeat.comWalleye Capital LLC Invests $4.74 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Walleye Capital LLC acquired a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 105,335 shares of the company's stDecember 2, 2024 | marketbeat.comPublic Sector Pension Investment Board Acquires New Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Public Sector Pension Investment Board bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 124,949 shares of the company's stock, valued at aDecember 2, 2024 | marketbeat.comIs Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?November 29, 2024 | uk.finance.yahoo.com19,128 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Acquired by Intech Investment Management LLCIntech Investment Management LLC bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 19,128 sharesNovember 29, 2024 | marketbeat.comThrivent Financial for Lutherans Makes New $2.08 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Thrivent Financial for Lutherans bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 46,257 shares of the company's stock, valued at approximately $November 29, 2024 | marketbeat.comInsider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Sells 26,000 Shares of StockNovember 28, 2024 | insidertrades.com50,000 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Purchased by Swedbank ABSwedbank AB purchased a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 50,000 shares of the company's stock, valued at approximateNovember 28, 2024 | marketbeat.com11,336 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Purchased by Advantage Alpha Capital Partners LPAdvantage Alpha Capital Partners LP bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 11,336 shNovember 27, 2024 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Buy" by BrokeragesProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has been given an average recommendation of "Buy" by the seven brokerages that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy ratNovember 26, 2024 | marketbeat.comAlgert Global LLC Sells 36,400 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Algert Global LLC trimmed its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 23.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 115,679 sharNovember 25, 2024 | marketbeat.comBNP PARIBAS ASSET MANAGEMENT Holding S.A. Makes New $5.67 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 125,898 shares of the company's stock, valued at approximateNovember 25, 2024 | marketbeat.comEagle Asset Management Inc. Lowers Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Eagle Asset Management Inc. reduced its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 17.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 294,280 shares ofNovember 24, 2024 | marketbeat.comProtagonist Therapeutics selects PN-881 as development candidateNovember 23, 2024 | markets.businessinsider.comVictory Capital Management Inc. Has $5.89 Million Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Victory Capital Management Inc. increased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 1,729.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1November 23, 2024 | marketbeat.comProtagonist Therapeutics price target raised to $67 from $51 at BTIGNovember 22, 2024 | markets.businessinsider.comProtagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - Should You Buy?Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - Should You Buy?November 22, 2024 | marketbeat.comPacer Advisors Inc. Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Pacer Advisors Inc. grew its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 405,061.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,734,090 shares of the company's stock after acquiring anNovember 22, 2024 | marketbeat.comProtagonist Therapeutics: Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development CandidateNovember 21, 2024 | finanznachrichten.deTD Cowen Remains a Buy on Protagonist Therapeutics (PTGX)November 21, 2024 | markets.businessinsider.comWedbush Expects Higher Earnings for Protagonist TherapeuticsProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Investment analysts at Wedbush raised their Q1 2025 earnings per share estimates for shares of Protagonist Therapeutics in a research note issued to investors on Tuesday, November 19th. Wedbush analyst Y. Zhong now forecasts that the coNovember 21, 2024 | marketbeat.comQuest Partners LLC Increases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Quest Partners LLC grew its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 885.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,947 shares of the company's stock aftNovember 21, 2024 | marketbeat.comProtagonist Therapeutics: Promising Growth with ICONIC Phase 3 Success and Strategic PartnershipsNovember 21, 2024 | markets.businessinsider.comProtagonist Therapeutics Poised for Growth: Promising Clinical Data and Strong Financial OutlookNovember 21, 2024 | markets.businessinsider.comArturo Md Molina Sells 1,906 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) StockNovember 20, 2024 | insidertrades.comProtagonist Therapeutics (NASDAQ:PTGX) Shares Gap Down - Here's WhyProtagonist Therapeutics (NASDAQ:PTGX) Shares Gap Down - What's Next?November 19, 2024 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Given Outperform Rating at WedbushWedbush reissued an "outperform" rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday.November 19, 2024 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Earns Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday.November 19, 2024 | marketbeat.comProtagonist and JNJ say icotrokinra study for PsO meets endpointNovember 19, 2024 | markets.businessinsider.comJanney Montgomery Scott LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Janney Montgomery Scott LLC purchased a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,249 shares of the companNovember 17, 2024 | marketbeat.com Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address How to piss off your liberal friends… and profit from it (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now PTGX Media Mentions By Week PTGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTGX News Sentiment▼1.100.71▲Average Medical News Sentiment PTGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTGX Articles This Week▼64▲PTGX Articles Average Week Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Roivant Sciences News Ascendis Pharma A/S News Revolution Medicines News Lantheus News Nuvalent News Blueprint Medicines News Elanco Animal Health News Legend Biotech News Cytokinetics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTGX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTGX Stock Alerts